mRECIST for HCC: Performance and novel refinements

医学 实体瘤疗效评价标准 临床终点 肿瘤科 进行性疾病 临床试验 疾病 肝细胞癌 内科学 放射科
作者
Josep Maria Llovet,Riccardo Antonio Lencioni
出处
期刊:Journal of Hepatology [Elsevier BV]
卷期号:72 (2): 288-306 被引量:754
标识
DOI:10.1016/j.jhep.2019.09.026
摘要

In 2010, modified RECIST (mRECIST) criteria were proposed as a way of adapting the RECIST criteria to the particularities of hepatocellular carcinoma (HCC). We intended to overcome some limitations of RECIST in measuring tumour shrinkage with local and systemic therapies, and also to refine the assessment of progression that could be misinterpreted with conventional RECIST 1.1, due to clinical events related to the natural progression of chronic liver disease (development of ascites, enlargement of lymph nodes, etc.). mRECIST has served its purpose since being adopted or included in clinical practice guidelines (European, American and Asian) for the management of HCC; it has also been instrumental for assessing response and time-to-event endpoints in several phase II and III investigations. Nowadays, mRECIST has become the standard tool for measurement of radiological endpoints at early/intermediate stages of HCC. At advanced stages, guidelines recommend both methods. mRECIST has been proven to capture higher objective response rates in tumours treated with molecular therapies and those responses have shown to be independently associated with better survival. With the advent of novel treatment approaches (i.e. immunotherapy) and combination therapies there is a need to further refine and clarify some concepts around the performance of mRECIST. Similarly, changes in the landscape of standard of care at advanced stages of the disease are pointing towards progression-free survival as a potential primary endpoint in some phase III investigations, as effective therapies applied beyond progression might mask overall survival results. Strict recommendations for adopting this endpoint have been reported. Overall, we review the performance of mRECIST during the last decade, incorporating novel clarifications and refinements in light of emerging challenges in the study and management of HCC.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
1秒前
可乐发布了新的文献求助10
1秒前
David完成签到,获得积分10
2秒前
2秒前
2秒前
爱笑绿柳完成签到,获得积分10
2秒前
cbs完成签到 ,获得积分10
3秒前
3秒前
能干的绯发布了新的文献求助10
3秒前
书包王发布了新的文献求助10
4秒前
杨凡华完成签到,获得积分10
4秒前
5秒前
科研通AI2S的应助被Shu舒采纳,获得10
5秒前
5秒前
领导范儿的应助被南海神尼采纳,获得10
5秒前
6秒前
共享精神的应助被vv采纳,获得10
6秒前
moss完成签到 ,获得积分10
6秒前
feihua1完成签到 ,获得积分10
6秒前
搜集达人的应助被爱笑绿柳采纳,获得10
6秒前
FashionBoy的应助被寒冷鸭子采纳,获得10
6秒前
欣喜若灵发布了新的文献求助10
7秒前
哈哈发布了新的文献求助10
7秒前
7秒前
7秒前
8秒前
8秒前
科研通AI65的应助被qwer采纳,获得10
8秒前
9秒前
9秒前
老实幻姬完成签到,获得积分10
9秒前
虚幻百川完成签到,获得积分0
10秒前
虚拟的水壶完成签到,获得积分10
10秒前
10秒前
momo123完成签到,获得积分10
11秒前
11秒前
123完成签到,获得积分20
11秒前
刘欣媛发布了新的文献求助10
11秒前
12秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8181155
求助须知:如何正确求助?哪些是违规求助? 9571140
关于积分的说明 21816740
捐赠科研通 7777528
什么是DOI,文献DOI怎么找? 3433436
关于科研通互助平台的介绍 2557664
邀请新用户注册赠送积分活动 2479482